Abstract:Background: Endothelial toxicity (by toxins, viral and bacterial sepsis) and associated inflammation can lead to acute and chronic vasculopathy leading to cardiac compromise. CD39 helps to maintain the endogenous antithrombotic profile of the endothelium. CD39 is an endothelial cell membrane-anchored enzyme that hydrolyses ATP and ADP to AMP. Subsequently, another enzyme CD73 further hydrolyses AMP to adenosine. The consequence of this important pathway is that pro-inflammatory (ATP) and pro-thrombotic (platelet aggregation amplifier, ADP) are converted to adenosine, which is anti-inflammatory, vasodilatory, and anti-thrombotic. CD39 enzyme activity drives this pathway. We have published before that CD39 is anti-thrombotic/anti-inflammatory (N Engl J Med. 2012;367(24):2322-2333; J Clin Invest. 2004;113(10):1440-1446) and also protects from ischaemia-reperfusion injury in heart and kidney (Eur Heart J. 2018;39(2):111-116; Am J Transplant. 2010;10(12):2586-2595) As a human disease correlate, CD39 activity and adenosine signalling is disrupted in human pulmonary hypertension (J Am Heart Assoc. 2020;9:e017404). Moreover, CD39-null mice are predisposed towards the development of experimental pulmonary hypertension after hypoxic injury (Am J Physiol Heart Circ Physiol 311: H286-H298, 2016). In this work, we demonstrate that the administration of a single dose of an endothelial cell toxin (monocrotaline pyrrole) leads to the development of vasculopathy and pulmonary hypertension as characterised by cardiac echo and right ventricular pressure studies. Single administration of endothelial (Vascular cell adhesion molecule, VCAM-1)-targeted soluble CD39 (Anti-VCAM-CD39) ameliorates pulmonary hypertension. Hypothesis: Targeted delivery of CD39 to the pulmonary endothelium will relieve pulmonary hypertension. Methods: 'Anti-VCAM-CD39' is novel therapeutic that contains a scFv recognising VCAM-1 fused to human soluble CD39. It is expressed as a single polypeptide from insect or mammalian cells and affinity purified using a FLAG-affinity tag. Prior work has demonstrated that Anti-VCAM-CD39 administration intravenously leads to dose-dependent prolongation of murine tail bleeding time only at doses above 1mg/kg. We have developed a murine model of pulmonary hypertension by a single administration of monocrotaline pyrrole (MCTP, 8mg/kg). Development of pulmonary hypertension was verified by cardiac echo showing abnormal (decreased) pulmonary acceleration time (PAT): pulmonary ejection (PET) ratio (an accepted parameter of pulmonary hypertension and increased heart weight ratio (heart weight/body weight x100). Pulmonary hypertension was also confirmed by right ventricular systolic pressure (RVSP) measurement. Cardiac echo was done with the Vevo2100 small animal high-frequency ultrasound machine and the 55Mhz MS550s transducer. RVSP was quantified in anaesthetised mice using a Millar pressure catheter (1.4Fr) inserted into the RV, via the right external jugular vein. Results:Development of pulmonary hypertension with single dose of MCTP 8mg/kg shows features of: 1. Increased endothelial VCAM-1 expression (mRNA expression, not shown) 2. Decreased PAT/PET ratios consistent with pulmonary hypertension (Table 1) with typical cardiac echo appearance (Fig. 1) 3. Increased cardiac weight:body weight ratio at D21 (vehicle 0.45±0.05; MCTP 0.6±0.1, p<0.05) 4. Leads to fibrin deposition (Carstairs stain, not shown). Anti-VCAM-CD39 ameliorates pulmonary hypertension, quantitated with cardiac echo and RVSP: 1.Single administration of Anti-VCAM-CD39 at doses of 0.4mg/kg and 1.0mg/kg at 72 h post MCTP improved (increased) PAT/PET ratio at D10 compared with saline control (Fig. 2). 2. Single administration of Anti-VCAM-CD39 at 1.0mg/kg reduced right ventricular systolic pressure (RVSP mmHg) at D10 consistent with amelioration of pulmonary hypertension. (Fig. 3). Effect of lower dose of Anti-VCAM-CD39 at 0.4mg/kg is awaited. Conclusion: 1. MCTP administration cause endothelial activation, VCAM-1 expression and vascular remodelling leading to a model of pulmonary hypertension with right ventricular pressure overload. 2. Single administration of Anti-VCAM-CD39 at doses 0.4mg/kg and 1.0mg/kg (below the threshold prolonging tail-bleeding time) leads to amelioration of pulmonary hypertension suggesting a novel new treatment for this condition. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Endothelial-Targeted CD39 Ameliorates Pulmonary Hypertension in a Murine Model of Endothelial Toxin Administration

Interruption of CD40 Pathway Improves Efficacy of Transplanted Endothelial Progenitor Cells in Monocrotaline Induced Pulmonary Arterial Hypertension.

Systemic Evaluation of Platelet and Leukocyte Activation and Interaction in A Rat Model of Pulmonary Arterial Hypertension

Abstract 18497: Attenuated Endothelial Cd39 Activity Mediates Vascular Remodeling in Pulmonary Arterial Hypertension

The biased apelin receptor agonist, MM07, reverses Sugen/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan

Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension

C-C motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator

Development of endothelial-targeted CD39 as a therapy for ischemic stroke

Selective Targeting HIF‐2α for Treatment of Pulmonary Arterial Hypertension

Novel p38 Mitogen-Activated Protein Kinase Inhibitor Reverses Hypoxia-Induced Pulmonary Arterial Hypertension in Rats

Purinergic Dysregulation in Pulmonary Hypertension

Smooth Muscle Myosin Inhibition: a Novel Therapeutic Approach for Pulmonary Hypertension.

Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition

TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats

Abstract 3629: Inhibition of Smooth Muscle Myosin, a Novel Therapeutic Approach for Pulmonary Hypertension

Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in mice

Abstract 12164: Inhibition of NOTCH3 Cleavage Effectively Reverses Pulmonary Hypertension in Rat and Mouse Models of Disease

Novel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension

Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand is A Novel Therapeutic Target in Pulmonary Arterial Hypertension

Enhanced Protection Against Pulmonary Hypertension With Sildenafil And Endothelial Progenitor Cell In Rats

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.